Lv1
48 积分 2023-04-02 加入
Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
2天前
已完结
免疫治疗耐药机制及应对策略的研究进展
5个月前
已完结
Hyperprogression during immunotherapy
1年前
已完结
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
1年前
已完结
Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer
1年前
已完结
[Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer]
1年前
已完结
A neutrophil response linked to tumor control in immunotherapy
1年前
已完结
Translational Surgery
1年前
已完结
Drug discovery and development
1年前
已关闭
皖公网安备34019202002308
